D Gareth Evans1, Elaine Harkness2, Fiona Lalloo3, Anthony Howell4. 1. Genesis Breast Cancer Prevention Centre, University Hospital of South Manchester NHS Trust, Manchester, UK Manchester Centre for Genomic Medicine, Central Manchester Foundation Trust, St. Mary's Hospital, Manchester, UK Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Christie Hospital, Manchester, UK The University of Manchester, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK. 2. Genesis Breast Cancer Prevention Centre, University Hospital of South Manchester NHS Trust, Manchester, UK The University of Manchester, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK Centre for Imaging Sciences, University of Manchester, Manchester, UK. 3. Manchester Centre for Genomic Medicine, Central Manchester Foundation Trust, St. Mary's Hospital, Manchester, UK. 4. Genesis Breast Cancer Prevention Centre, University Hospital of South Manchester NHS Trust, Manchester, UK Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Christie Hospital, Manchester, UK The University of Manchester, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
Abstract
BACKGROUND: The risks of breast cancer associated with BRCA1 and BRCA2 mutations vary considerably across studies but few have assessed prospective risks, which are likely to provide more reliable risk estimates for women undergoing presymptomatic testing. METHODS: Prospective breast cancer risks were assessed in 254 unaffected women with BRCA1 mutations and 238 with BRCA2 mutations. Rates of breast cancer were calculated allowing for lead time bias and censored at time of risk reducing mastectomy. Degree of family history was assessed using the Manchester score and genotyping was undertaken using 18 single-nucleotide polymorphisms (SNPs) linked to breast cancer. RESULTS: Nineteen breast cancers occurred in women undergoing presymptomatic testing for BRCA1 and 23 for BRCA2. Breast cancer incidence for BRCA2 was marginally higher than BRCA1 at 20.05 per 1000 in BRCA2 compared with 16.20 per 1000 in BRCA1. Penetrance estimates to 70 years of age adjusted for a 6-month lead time and oophorectomy using Kaplan-Meier analysis were 55.1% (95% CI 36.5% to 75.6%) for BRCA1 and 71.5% (95% CI 53.2% to 87.6%). Breast cancer cases were associated with stronger family histories and higher SNP aggregate scores in BRCA2. CONCLUSIONS: Prospective breast cancer risks in women in the UK are high especially for BRCA2 families ascertained on the basis of high risk. Women undergoing presymptomatic testing for BRCA2 should be quoted a wide range of possible breast cancer risks and should be steered within that range based on degree of family history, non-genetic risk factors and possibly SNP testing. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: The risks of breast cancer associated with BRCA1 and BRCA2 mutations vary considerably across studies but few have assessed prospective risks, which are likely to provide more reliable risk estimates for women undergoing presymptomatic testing. METHODS: Prospective breast cancer risks were assessed in 254 unaffected women with BRCA1 mutations and 238 with BRCA2 mutations. Rates of breast cancer were calculated allowing for lead time bias and censored at time of risk reducing mastectomy. Degree of family history was assessed using the Manchester score and genotyping was undertaken using 18 single-nucleotide polymorphisms (SNPs) linked to breast cancer. RESULTS: Nineteen breast cancers occurred in women undergoing presymptomatic testing for BRCA1 and 23 for BRCA2. Breast cancer incidence for BRCA2 was marginally higher than BRCA1 at 20.05 per 1000 in BRCA2 compared with 16.20 per 1000 in BRCA1. Penetrance estimates to 70 years of age adjusted for a 6-month lead time and oophorectomy using Kaplan-Meier analysis were 55.1% (95% CI 36.5% to 75.6%) for BRCA1 and 71.5% (95% CI 53.2% to 87.6%). Breast cancer cases were associated with stronger family histories and higher SNP aggregate scores in BRCA2. CONCLUSIONS: Prospective breast cancer risks in women in the UK are high especially for BRCA2 families ascertained on the basis of high risk. Women undergoing presymptomatic testing for BRCA2 should be quoted a wide range of possible breast cancer risks and should be steered within that range based on degree of family history, non-genetic risk factors and possibly SNP testing. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544
Authors: Pål Møller; Kukatharmini Tharmaratnam; Anthony Howell; Paula Stavrinos; Sarah Sampson; Andrew Wallace; Anthony J Maxwell; Anne Irene Hagen; D Gareth Evans Journal: Breast Cancer Res Treat Date: 2015-06-03 Impact factor: 4.872
Authors: Valérie de Crécy-Lagard; Pietro Boccaletto; Carl G Mangleburg; Puneet Sharma; Todd M Lowe; Sebastian A Leidel; Janusz M Bujnicki Journal: Nucleic Acids Res Date: 2019-03-18 Impact factor: 16.971
Authors: Alexander Liede; Carol A Mansfield; Kelly A Metcalfe; Melanie A Price; Carrie Snyder; Henry T Lynch; Sue Friedman; Justyna Amelio; Joshua Posner; Steven A Narod; Geoffrey J Lindeman; D Gareth Evans Journal: Breast Cancer Res Treat Date: 2017-06-17 Impact factor: 4.872
Authors: D Gareth Evans; Sacha J Howell; Ashu Gandhi; Elke M van Veen; Emma R Woodward; James Harvey; Lester Barr; Andrew Wallace; Fiona Lalloo; Mary Wilson; Emma Hurley; Yit Lim; Anthony J Maxwell; Elaine F Harkness; Anthony Howell Journal: Breast Cancer Res Treat Date: 2021-07-26 Impact factor: 4.872